α-Vinylornithine | 111656-37-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: α-Vinylornithine
• 英文别名: 5-amino-2-azaniumyl-2-ethenylpentanoate
• CAS: 111656-37-2
• 化学式: C₇H₁₄N₂O₂
• 分子量: 158.2
• InChiKey: BBAGHEILTMBQPL-UHFFFAOYSA-N

物化性质

• 沸点：
  341.6±42.0 °C(Predicted)
• 密度：
  1.120±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -3
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  89.3
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  α-Vinylornithine 、 S-乙基异硫脲氢溴酸盐 在 sodium hydroxide 作用下， 反应 36.0h， 以59%的产率得到α-Vinylarginine
  参考文献：
  名称：

  Pedersen, Michelle L.; Berkowitz, David B., Journal of Organic Chemistry, 1993, vol. 58, # 25, p. 6965 - 6975

  摘要：

  DOI：
• 作为产物：
  描述：

  N^α-Benzoylornithine 在 盐酸 、 1-己烯 、 磺酰氯 、 sodium trimethoxyborohydride 、 臭氧 、 三乙胺 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 67.0h， 生成 α-Vinylornithine
  参考文献：
  名称：

  Pedersen, Michelle L.; Berkowitz, David B., Journal of Organic Chemistry, 1993, vol. 58, # 25, p. 6965 - 6975

  摘要：

  DOI：

文献信息

• Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension
  申请人：G.D. Searle & Co.

  公开号：US20030220521A1

  公开（公告）日：2003-11-27

  Renal-selective prodrugs are described which are preferentially converted in the kidney to compounds capable of inhibiting synthesis of catecholamine-type neurotransmitters involved in renal sympathetic nerve activity. The prodrugs described herein are derived from inhibitor compounds capable of inhibiting one or more of the enzymes involved in catecholamine synthesis, such compounds being classifiable as tyrosine hydroxylase inhibitors, or as dopa-decarboxylase inhibitors, or as dopamine-&bgr;-hydroxylase inhibitors. These inhibitor compounds are linked to a chemical moiety, such as a glutamic acid derivative, by a cleavable bond which is recognized selectively by enzymes located predominantly in the kidney. The liberated inhibitor compound is then available in the kidney to inhibit one or more of the enzymes involved in catecholamine synthesis. Inhibition of renal catecholamine synthesis can suppress heightened renal nerve activity associated with sodium-retention related disorders such as hypertension. Conjugates of particular interest are glutamyl derivatives of dopamine-&bgr;-hydroxylase inhibitors, of which N-acetyl-&ggr;-glutamyl fusaric acid hydrazide (shown below) is preferred. 1

  本文描述了一种肾选择性的前药，其在肾脏中优先转化为能够抑制参与肾交感神经活动的儿茶酚型神经递质合成的化合物。本文所描述的前药来源于能够抑制儿茶酚合成中的一个或多个酶的抑制剂化合物，这些化合物可分类为酪氨酸羟化酶抑制剂，多巴脱羧酶抑制剂或多巴胺-&bgr;-羟化酶抑制剂。这些抑制剂化合物通过可被肾脏中大量存在的酶选择性识别的可裂解键与化学基团（如谷氨酸衍生物）连接。释放的抑制剂化合物然后可在肾脏中用于抑制儿茶酚合成中的一个或多个酶。抑制肾脏儿茶酚合成可抑制与钠潴留相关的疾病（如高血压）相关的增强肾脏神经活动。特别感兴趣的共轭物是多巴胺-&bgr;-羟化酶抑制剂的谷氨酰衍生物，其中N-乙酰-&ggr;-谷氨酰富萨酸肼（如下图所示）是首选。1
• Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension
  申请人：G.D. Searle & Co.

  公开号：US20040101523A1

  公开（公告）日：2004-05-27

  Renal-selective prodrugs are described which are preferentially converted in the kidney to compounds capable of inhibiting synthesis of catecholamine-type neurotransmitters involved in renal sympathetic nerve activity. The prodrugs described herein are derived from inhibitor compounds capable of inhibiting one or more of the enzymes involved in catecholamine synthesis, such compounds being classifiable as tyrosine hydroxylase inhibitors, or as dopa-decarboxylase inhibitors, or as dopamine-&bgr;-hydroxylase inhibitors. These inhibitor compounds are linked to a chemical moiety, such as a glutamic acid derivative, by a cleavable bond which is recognized selectively by enzymes located predominantly in the kidney. The liberated inhibitor compound is then available in the kidney to inhibit one or more of the enzymes involved in catecholamine synthesis. Inhibition of renal catecholamine synthesis can suppress heightened renal nerve activity associated with sodium-retention related disorders such as hypertension. Conjugates of particular interest are glutamyl derivatives of dopamine-&bgr;-hydroxylase inhibitors, of which N-acetyl-&ggr;-glutamyl fusaric acid hydrazide (shown below) is preferred. 1

  本文描述了肾脏选择性前药，这些前药被优先转化为能够抑制与肾脏交感神经活动相关的儿茶酚类神经递质合成的化合物。所述前药源自能够抑制儿茶酚类合成中涉及的一个或多个酶的抑制剂化合物，这些化合物可分类为酪氨酸羟化酶抑制剂，或多巴脱羧酶抑制剂，或是多巴胺-β-羟化酶抑制剂。这些抑制剂化合物与化学基团（例如谷氨酸衍生物）通过可被肾脏内的酶特异性识别的可切断键连接。被释放的抑制剂化合物随后可在肾脏中抑制一个或多个涉及儿茶酚类合成的酶。抑制肾脏儿茶酚类合成可以抑制与钠潴留相关的疾病（如高血压）所伴随的过度肾脏神经活动。特别感兴趣的结合物是多巴胺-β-羟化酶抑制剂的谷氨酰衍生物，其中N-乙酰-γ-谷氨酰菌核酸酸肼（如下图所示）是首选。1
• Alpha-vinyl-alpha-aminoacids and their esters and pharmaceutical compositions containing them
  申请人：Merck & Co., Inc.

  公开号：EP0008657A1

  公开（公告）日：1980-03-19

  Novel α-vinyl-α-aminoacids having the formula wherein R has the signification given in the description and R1 is H or C1-C18 alkyl, e.g. the compounds of the formulas and are prepared e.g. by treating a derivative of the formula with a strong base and an alkylating agent, followec by hydrolysis. The novel aminoacids are useful for treating hypertension, as gastric secretion inhibitors, antihistamine antiallergics and antitumor agents. Furthermore, they exhibit enzyme inhibition.

  新型α-乙烯基-α-氨基酸，其式如下 其中 R 具有说明中给出的含义，R1 是 H 或 C1-C18 烷基，例如式子为 和 式的衍生物与强碱和烷基反应制备。 用强碱和烷基化剂处理，然后通过水解制备。新型氨基酸可用于治疗高血压、胃分泌抑制剂、抗组胺抗过敏剂和抗肿瘤剂。此外，它们还具有酶抑制作用。
• Simultaneous Amino and Carboxyl Group Protection for .alpha.-Branched Amino Acids
  作者：David B. Berkowitz、Michelle L. Pedersen

  DOI：10.1021/jo00097a064

  日期：1994.9
• A general synthesis of α-vinyl-α-amino acids
  作者：W.J. Greenlee、D. Taub、A.A. Patchett

  DOI：10.1016/s0040-4039(01)95122-6

  日期：1978.1